文献速递乳腺癌

年轻乳腺癌患者BRCA1/2致病性变异类型与位置和表型及预后的关联:国际队列研究

Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study.
PubMed 文献 · Ann Oncol · 2025-11-17

该国际多中心回顾性队列研究纳入≤40岁诊断浸润性乳腺癌的BRCA携带者,分析致病变异(LP/PV)类型与位置对临床病理特征及生存的影响。在3294例可分析患者中,BRCA1截短变异与更差OS相关(HR 2.00,95%CI 1.17-3.41),错义变异与更好OS相关(BRCA1 HR 0.48,95%CI 0.28-0.84;BRCA2 HR 0.17,95%CI 0.03-0.96)。变异位置亦与生存相关,提示基于个体BRCA变异的精准策略具有潜力。

要点

  • BRCA1截短变异较非截短变异与更差OS相关(HR 2.00,95%CI 1.17-3.41)。
  • BRCA1和BRCA2错义变异均与更好OS相关(HR 0.48和0.17)。
  • BRCA1 LP/PV位于外显子2、10、19之外与改善OS相关。

核心结论

  • BRCA1/2致病变异的特定类型和位置与年轻乳腺癌患者的生存预后相关,支持基于个体变异的定制化临床策略。

研究设计与样本

  • 国际多中心医院回顾性队列研究(BRCA BCY协作组,NCT03673306),纳入2000年1月至2020年12月≤40岁诊断浸润性乳腺癌且BRCA1/2 LP/PV信息详尽的携带者,共3294例(BRCA1 2080例,BRCA2 1214例)来自109个中心。

主要发现

  • LP/PV类型分布与基线临床病理特征无有意义的关联。
  • BRCA1蛋白截短变异较非截短变异与更差OS相关(HR 2.00,95%CI 1.17-3.41);BRCA2呈相似但未达显著的趋势。
  • 错义变异与更好OS相关:BRCA1 HR 0.48(95%CI 0.28-0.84),BRCA2 HR 0.17(95%CI 0.03-0.96)。
  • BRCA1 LP/PV位于外显子2、10、19之外与改善OS相关。
  • BRCA2 LP/PV位于外显子15-26及其他区域较外显子10与更差DFS相关,OS无显著差异。

临床怎么用

  • 对年轻乳腺癌BRCA携带者,可结合变异类型(截短/错义)和位置评估预后风险,辅助个体化随访与治疗决策。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The clinical implications of specific pathogenic and likely pathogenic variant (LP/PV) types and locations in the BRCA1 orBRCA2 tumor-suppressor genes remain to be elucidated. PATIENTS AND METHODS: The BRCA BCY Collaboration (NCT03673306) is an international, multicenter, hospital-based, retrospective cohort study that included BRCA carriers diagnosed with invasive breast cancer at the age of ≤40 years between January 2000 and December 2020. In this analysis, only patients with detailed available information on LP/PVs in the BRCA genes were included. Clinicopathological features and survival outcomes [disease-free survival (DFS) and overall survival (OS)] were investigated according to LP/PV type [insertion-deletion (indel) versus single-nucleotide variants versus copy number variations; truncating versus non-truncating LP/PVs; frameshift versus nonsense versus splicing versus missense LP/PVs] and location (exon involved and protein domain). RESULTS: Out of 5660 patients from 109 centers worldwide, 3294 were eligible for the present analysis (2080 BRCA1 and 1214 BRCA2). The distribution of LP/PV types showed no meaningful associations with baseline clinicopathological features. BRCA1 protein-truncating variants were associated with worse OS compared with non-truncating variants [hazard ratio (HR) 2.00, 95% confidence interval (CI) 1.17-3.41]. A similar, though non-significant, trend was observed for BRCA2. Missense variants were linked to better OS for both BRCA1 (HR 0.48, 95% CI 0.28-0.84) and BRCA2 carriers (HR 0.17, CI 0.03-0.96). Regarding variant location, BRCA1 LP/PVs outside exons 2, 10, and 19 were associated with improved OS. In BRCA2, LP/PVs located in exons 15-26 and other regions were linked to worse DFS compared with those in exon 10, with no significant differences in OS. CONCLUSIONS: This study advances our understanding of the influence of specific types of BRCA LP/PVs on breast cancer characteristics and outcomes. A deeper understanding of these variant-specific features will drive future research and support the development of tailored clinical strategies based on individual BRCA variant.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Toss A, Blondeaux E, Tenedini E, et al. Association between type and location of germline BRCA1/2 pathogenic or likely pathogenic variants with phenotype and prognosis in young patients with breast cancer: results from an international cohort study. Ann Oncol. 2025. PMID: 41260260. doi:10.1016/j.annonc.2025.11.004

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。